On the accuracy of calculation of the mean residence time of drug in the body and its volumes of distribution based on the assumption of central elimination

References

• Abernethy DR, Divoll M, Greenblatt DJ, et al. (1984). Absolute bioavailability of imipramine: influence of food. Psychopharmacology 83:104–6
   PubMed Web of Science ®Google Scholar
• Benet LZ, Galeazzi RL. (1979). Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci 68:1071–4
   PubMed Web of Science ®Google Scholar
• Berezhkovskiy LM. (2004). Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. J Pharm Sci 93:40
   Web of Science ®Google Scholar
• Berezhkovskiy LM. (2010). A valid equation for the well-stirred perfusion limited physiologically based pharmacokinetic model that consistently accounts for the blood–tissue drug distribution in the organ and the corresponding valid equation for the steady state volume of distribution. J Pharm Sci 99:475–85
   PubMed Web of Science ®Google Scholar
• Berezhkovskiy LM. (2011a). The corrected traditional equations for calculation of hepatic clearance that account for the difference in drug ionization in extracellular and intracellular tissue water and the corresponding corrected PBPK equation. J Pharm Sci 100:1167–83
   PubMed Web of Science ®Google Scholar
• Berezhkovskiy LM. (2011b). The influence of hepatic transport on the distribution volumes and mean residence time of drug in the body and the accuracy of estimating these parameters by the traditional pharmacokinetic calculations. J Pharm Sci 100:5031–47
   PubMed Web of Science ®Google Scholar
• Brøsen K, Gram LF. (1988). First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype. Clin Pharmacol Ther 43:400–6
   PubMed Web of Science ®Google Scholar
• Ciraulo DA, Barnhill JG, Jaffe JH. (1988). Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. Clin Pharmacol Ther 43:509–18
   PubMed Web of Science ®Google Scholar
• Eberts FS, Philopoulos Y, Reineke LM, Vliek RW. (1980). Disposition of 14C-alprazolam, a new anxiolytic-antidepressant, in man. Pharmacologist 22:279
   Google Scholar
• Guentert TW, Holford NH, Coates PE, et al. (1979). Quinidine pharmacokinetics in man: choice of a disposition model and absolute bioavailability studies. J Pharmacokinet Biopharm 7:315–30
   PubMedGoogle Scholar
• Greenblatt DJ, Pfeifer HJ, Ochs HR, et al. (1977). Pharmacokinetics of quinidine in humans after intravenous, intramuscular and oral administration. J Pharmacol Exp Ther 202:365–78
   PubMed Web of Science ®Google Scholar
• Hardy BG, Schentag JJ. (1988). Lack of effect of cimetidine on the metabolism of quinidine: effect on renal clearance. Int J Clin Pharmacol Ther Toxicol 26:388–91
   PubMed Web of Science ®Google Scholar
• Hughes IE, Ilett KF, Jellett LB. (1975). The distribution of quinidine in human blood. Br J Clin Pharmacol 2:521–5
   PubMed Web of Science ®Google Scholar
• Iwatsubo T, Hirota N, Ooie T, et al. (1997). Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:147–71
   PubMed Web of Science ®Google Scholar
• Jann MW, Grimsley SR, Gray EC, Chang WH. (1993). Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 24:161–76
   PubMed Web of Science ®Google Scholar
• Johansson KA, Appelgren C, Borg KO, Elofsson R. (1974). Binding of two adrenergic beta-receptor antagonists, alprenolol and H 93-26, to human serum proteins. Acta Pharm Suec 11:333–46
   PubMedGoogle Scholar
• Miller AK, Adir J, Vestal RE. (1990). Excretion of tolbutamide metabolites in young and old subjects. Eur J Clin Pharmacol 38:523–4
   PubMed Web of Science ®Google Scholar
• Miners JO, Foenander T, Wanwimolruk S, et al. (1982). The effect of sulphinpyrazone on oxidative drug metabolism in man: inhibition of tolbutamide elimination. Eur J Clin Pharmacol 22:321–6
   PubMed Web of Science ®Google Scholar
• Nagy A, Johansson R. (1975). Plasma levels of imipramine and desipramine in man after different routes of administration. Naunyn Schmiedebergs Arch Pharmacol 290:145–60
   PubMed Web of Science ®Google Scholar
• Nakashima E, Benet LZ. (1988). General treatment of mean residence time, clearance, and volume parameters in linear mammillary models with elimination from any compartment. J Pharmacokinet Biopharm 16:475–92
   PubMedGoogle Scholar
• Obach RS. (1999). Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350–9
   PubMed Web of Science ®Google Scholar
• Oppenheimer JH, Schwartz JL, Surks MI. (1975). Determination of common parameters for iodothyronine metabolism and distribution in man by noncompartmental analysis. J Clin Endocrinol Metab 41:319–24
   PubMed Web of Science ®Google Scholar
• Regårdh CG, Borg KO, Johansson R, et al. (1974). Pharmacokinetic studies on the selective beta1-receptor antagonist metoprolol in man. J Pharmacokinet Biopharm 2:347–64
   PubMedGoogle Scholar
• Regårdh CG, Jordö L, Ervik M, et al. (1981). Pharmacokinetics of metoprolol in patients with hepatic cirrhosis. Clin Pharmacokinet 6:375–88
   PubMed Web of Science ®Google Scholar
• Rodgers T, Rowland M. (2006). Physiologically based pharmacokinetic modeling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95:1238–57
   PubMed Web of Science ®Google Scholar
• Rodgers T, Rowland M. (2007). Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res 24:918–33
   PubMed Web of Science ®Google Scholar
• Shibata Y, Takahashi H, Chiba M, Ishii Y. (2002). Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method. Drug Metab Dispos 30:892–6
   PubMed Web of Science ®Google Scholar
• Smith RB, Kroboth PD, Vanderlugt JT, et al. (1984). Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. Psychopharmacology 84:452–6
   PubMed Web of Science ®Google Scholar
• Turner D, editor. (2008). Simcyp Population-based ADME Simulator User Manual, Version 8. 232 pages including appendices and references. Simcyp Limited, Blades Enterprise Centre, Sheffield, UK. The referred numerical values were generated by Simcyp Simulator
   Google Scholar
• von Moltke LL, Greenblatt DJ, Harmatz JS, Shader RI. (1993). Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. Pharmacology 47:268–76
   PubMed Web of Science ®Google Scholar
• Wagner JG. (1976). Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data. J Pharmacokinet Biopharm 4:443–67
   PubMedGoogle Scholar
• Weiss M, Forster W. (1979). Pharmacokinetic model based on circulatory transport. Eur J Clin Pharmacol 16:287–93
   Web of Science ®Google Scholar
• Williams RL, Blaschke TF, Meffin PJ, et al. (1977). Influence of acute viral hepatitis on disposition and plasma binding of tolbutamide. Clin Pharmacol Ther 21:301–9
   PubMed Web of Science ®Google Scholar